Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two ...
In this study, researchers aimed to examine survival outcomes with elraglusib plus chemotherapy compared to chemotherapy alone in untreated mPDAC.
Based on positive phase 3 trial results, a New Drug Application will be submitted to the Food and Drug Administration for daraxonrasib.
SurvivorNet on MSN
New targeted drug could double survival for some with advanced pancreatic cancer: What to know about daraxonrasib
In a phase 3 trial for pancreatic ductal adenocarcinoma (PDAC), daraxonrasib significantly improved survival to 13.2 months, ...
New research provides compelling evidence that Barrett’s esophagus underlies all cases of esophageal adenocarcinoma, even when it is no longer visible.
Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II ...
Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results